Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy
Authors:
Open Access
- 7 November 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 9 (23) , 9027-9035
Abstract
The risk of infection in patients receiving immune checkpoint inhibitor (ICI) therapy is not well understood. Immune‐related adverse events requiring immunosuppressive therapy may impact infection risk. ICIs may induce an exaggerated immune response to latent infection. We assessed the incidence and risk factors for infections during cancer ICI therapy. A retrospective chart review of solid tumor patients treated with ICIs was conducted. Infectious episodes were defined as those where a microbial organism was cultured or identified through polymerase chain reaction. Infections which occurred during and up to 1 year following ICI therapy were considered “post‐ICI” infections. Of 327 patients, 47% had melanoma and 36% had non‐small cell lung cancer. The majority (77%) received single agent anti‐PD(L)1 antibody, 14% received combination anti‐PD(L)1 and anti‐CTLA4 antibody, and 9% single agent anti‐CTLA4 antibody. Infections occurred in 89 (27%) in the post‐ICI compared with 111 (34%) patients in the pre‐ICI period (p = 0.57). The most common types of infection were respiratory, genitourinary, and cutaneous infections. On multivariate analysis, only age over 67 years significantly predicted for development of infection on ICI (HR 1.73, p = 0.04). We did not find receipt of corticosteroids, combination ICI therapy, diabetes, or gender to significantly impact on infection risk. The rate of microbial infections among solid tumor patients receiving ICI therapy was 27%, comparable to the infection rate of 34% in the same cohort of patients in the period pre‐ICI therapy. Age over 67 years was significantly associated with infection post‐ICI.Keywords
This publication has 19 references indexed in Scilit:
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphomaActa Oncologica, 2016
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialThe Lancet Oncology, 2015
- Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infectionsImmunology, 2015
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- Significant Impairment in Immune Recovery After Cancer TreatmentNursing Research, 2009
- Immunosenescence and Vaccination in Nursing Home ResidentsClinical Infectious Diseases, 2009
- Increased Risk of Common Infections in Patients with Type 1 and Type 2 Diabetes MellitusClinical Infectious Diseases, 2005
- Quantifying the Risk of Infectious Diseases for People With DiabetesDiabetes Care, 2003
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987